BPC-157 dosage for a small / toy breed
under 22 lb (10 kg)
The short answer
For a dog weighing under 22 lb (10 kg), the dose of BPC-157 reported in the literature is 4–100 mcg per day, given once daily, over 2-4 weeks. It is studied in this weight class primarily for gastrointestinal issues, joint injury, post-surgical recovery. These figures are reported as published and are not recommendations — the dose for an individual dog must be set by a veterinarian who has examined the animal.
Worked examples at specific weights
Calculated from the reported range of 2–10 mcg per kg of body weight.
| Body weight | Calculated dose range | Frequency |
|---|---|---|
| 2 kg (4 lb) | 4–20 mcg | Once daily |
| 5 kg (11 lb) | 10–50 mcg | Once daily |
| 8 kg (18 lb) | 16–80 mcg | Once daily |
For an exact figure at your dog's weight, use the dose calculator.
Typical breeds in this weight class
Chihuahua, Yorkshire Terrier, Dachshund, Pomeranian, Shih Tzu and similarly sized dogs generally fall within under 22 lb (10 kg). Weigh your dog rather than estimating — dosing is calculated per kilogram and an estimate that is out by a few kilos changes the figure materially, particularly at the smaller end.
Common questions
How much BPC-157 for a small / toy breed?+
For a dog in the under 22 lb (10 kg) range, the reported dose is 4–100 mcg per day, given once daily, typically for 2-4 weeks. At a representative weight of 5 kg (about 11 lb), that works out to roughly 10–50 mcg per dose. These figures are reported from the source literature and are not recommendations.
How often should a small / toy breed be given BPC-157?+
Once daily is the reported frequency, over a course of 2-4 weeks. See the cycling guide for how breaks are structured.
Is BPC-157 safe for a small / toy breed?+
BPC-157 has the most directly relevant safety data of any compound on this site as it applies to dogs. A dedicated preclinical toxicity evaluation covering mice, rats, rabbits and dogs reported that it was well tolerated with no serious toxicity, no genotoxicity and no embryo-fetal toxicity; the single notable finding was a decrease in creatinine at 2 mg/kg, which resolved spontaneously after two weeks of withdrawal and did not occur at lower doses. Local irritation was mild. The meaningful caveat is duration rather than dose — those studies covered single and repeated dosing, not months of continuous administration.
References
- 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
- 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
- 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
Other weight classes: BPC-157 for a medium breed, BPC-157 for a large / giant breed.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.